CM Hospitalar SA (VVEO3) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of CM Hospitalar SA BRL 2.28, price BRL 0.76, upside +200.0%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CM Hospitalar SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range R$0.5600 – R$25.31 · fair‑value band R$2.28 – R$4.52 · the R$0.7600 price screens below the R$2.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow CM Hospitalar in your weekly email
Every Wednesday you see whether CM Hospitalar is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil.
Show more
CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers material products for cardiac, surgical, urinary, diagnosis, sterilization, wound management, hygiene and protection, infusion, clinical nutrition, orthopedic, and respiratory; and medications, such as painkillers, anesthetics, anti-allergy, antibiotics, antiemetics, antifungals, anti-inflammatory, special control, several, and oncology. It also provides materials for respiratory assistance, therapy, anti-inflammatories, anti-tnf, antacid, antiandrogens, antianemics, anti-asthmatics, antibiotics, anticoagulant, anticonvulsant, monoclonal antibody, anti-growth, antidepressants, antidiabetic drug, antidiuretics, antidote, antiemetics and antinauseants, anti-migraine, antiepileptics, antiestrogens, antifibrinolytics, antiflatulents, antifungals, antihemorrhagic drug, antimicrobial, antineoplastics, antiparathyroid, antiparkinsonian, antipsychotics, systemic antipsoriasis, antirheumatic drugs, anti-varicose, antivirals, beta-blockers, carbohydrate, cycloplegic, contraceptives, contrast, special control, corticosteroids, topical debriding agent, diuretics, several, electrolyte, pancreatic enzyme, erythropoietins, uterine stimulant, cardiac stimulators, growth factor, granulocyte colony stimulating factor, gastroprokinetics, systemic hemostatics, heparins, hepatoprotective and lipotropic agents, hormone, adenohypophyseal hormones, growth hormones, immunoglobulins, immunosuppressants, labor induction drugs, proton pump inhibitor, phosphodiesterase and bone resorption inhibitor, platelet aggregation inhibitors, adenosine diphosphate receptor antagonists, proton pump inhibitors, interleukin inhibitors, subtilisin/kexin type 9 proprotein convertase inhibitors, calcium reabsorption inhibitors, materials, medications, nutrition, therapy, orthopedic therapy. CM Hospitalar S/A was incorporated in 2010 and is headquartered in São Paulo, Brazil.
Stock analysis
CM Hospitalar SA (VVEO3) currently trades at R$0.7600, while our model-based Fair Value estimate is R$2.28, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of R$20.71 per share, and 24 of the 24 models we run sit above the R$0.7600 price.
Bear case: the Multiples group reads lowest at R$1.27, and 0 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: R$2.28 (bear) to R$4.52 (bull), the price of R$0.7600 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
CM Hospitalar SA reported revenue of R$11.6B in FY2025 versus R$6.2B in FY2021, a compound +16.8%/yr. Reported net income was R$18.2M in FY2025, compounding −53.6%/yr from FY2021.
Key figures
Market cap R$240M (≈ $46.1M) · P/E ratio 12.7 · P/S ratio 0.02 · EPS (TTM) R$0.0600 · Net margin 0.2% · Return on equity 1.1% · Return on assets (EBIT) 3.1% · Operating margin 4.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 59% below its 52-week high and 36% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at 200%, VVEO3 screens cheaper than that median.
Fair Value models
Bear R$2.28Fair Value R$2.28Bull R$4.52
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$0.0449 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.1%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in BRL ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in BRL: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+18.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 5%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 79 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (TTM)1.1% · Below median
Return on assets3.9% · Top 25%
Net margin (TTM)0.2% · Bottom 25%
Operating margin (TTM)4.0% · Above median
Growth and dividend
Revenue growth1.7% · Below median
Dividend yield (TTM)24.1% · Top 25%
Balance sheet
Debt / equity1.26× · Highest 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/E (TTM)12.7× · Cheaper than median
P/B0.12× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CM Hospitalar SA Fair Value". https://www.fairvalue-calculator.com/stock/VVEO3
Frequently asked questions
Is CM Hospitalar SA (VVEO3) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of R$2.28 versus a price of R$0.7600, about +200% upside (undervalued).
What is the fair value of VVEO3?
Our model-based fair value for CM Hospitalar SA is R$2.28 (as of Sep 24, 2026), built from audited fundamentals. The current price: R$0.7600.
What is the quality score of VVEO3?
CM Hospitalar SA has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CM Hospitalar SA (VVEO3)?
Our model-based price target is the fair value of R$2.28 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario R$2.28, optimistic scenario R$4.52. It is a calculation from audited fundamentals, not an analyst target.
What is the CM Hospitalar SA stock forecast for 2026?
Our models put fair value at R$2.28, about +200% upside versus a price of R$0.7600 (undervalued). Cautious scenario R$2.28, optimistic scenario R$4.52. The calculation is refreshed regularly with new filings.
What is the revenue of CM Hospitalar SA (VVEO3)?
CM Hospitalar SA reported trailing-twelve-month revenue of about R$11.6B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of CM Hospitalar SA (VVEO3)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CM Hospitalar SA it is R$2.28 per share (as of Sep 24, 2026), against a price of R$0.7600. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is CM Hospitalar SA stock overvalued or undervalued in 2026?
As of Sep 24, 2026, VVEO3 trades below its calculated fair value: price R$0.7600, fair value R$2.28, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VVEO3?
No. The price is what the market pays today (R$0.7600); the fair value is what the company's own numbers justify (R$2.28). For CM Hospitalar SA the two are R$1.52 per share apart. That gap is exactly why we show both numbers side by side.
How much is CM Hospitalar SA worth?
The market values CM Hospitalar SA at about R$240M (market capitalisation, as of Sep 24, 2026). Per share that is R$0.7600; our models calculate a fair value of R$2.28 per share.
What do the bullish and bearish scenarios say about VVEO3?
Our models span a range for CM Hospitalar SA: cautious scenario R$2.28, base R$2.28, optimistic R$4.52 per share (as of Sep 24, 2026, price R$0.7600). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VVEO3?
CM Hospitalar SA trades at a price-to-earnings ratio of 12.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$2.28 is built from several models across several years. Other multiples: P/B 0.1, P/S 0.0, EV/EBITDA 3.3.
How solid is the balance sheet of CM Hospitalar SA (VVEO3)?
Balance-sheet figures for CM Hospitalar SA (as of Sep 24, 2026): return on equity 1.1%, debt of 1.26 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is VVEO3 from its 52-week high?
CM Hospitalar SA trades at R$0.7600, about 59% below its 52-week high of R$1.84 and 36% above the low of R$0.5600 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of R$2.28 is for.
Which stocks are comparable to CM Hospitalar SA?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CM Hospitalar SA stock attractive at the current price?
The data as of Sep 24, 2026: price R$0.7600, calculated fair value R$2.28 (+200%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VVEO3 calculated?
We run CM Hospitalar SA through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$2.28, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. CM Hospitalar SA currently trades 67 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CM Hospitalar SA (VVEO3)?
The closing price on Sep 28, 2026 was R$0.7600. Our model-based fair value is R$2.28, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CM Hospitalar SA right now?
The price is below even our cautious bear case (R$2.28). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (R$2.28 to R$4.52) leaves room in how you read the outcome.
Key figures of CM Hospitalar SA
How large is the market capitalisation of CM Hospitalar SA (VVEO3)?
The market capitalisation of CM Hospitalar SA is R$240M (≈ $46.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CM Hospitalar SA (VVEO3)?
The price-to-sales ratio of CM Hospitalar SA is 0.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CM Hospitalar SA (VVEO3)?
Earnings per share at CM Hospitalar SA are R$0.0600 (price ÷ EPS = P/E 12.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CM Hospitalar SA (VVEO3)?
The net margin of CM Hospitalar SA is 0.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CM Hospitalar SA (VVEO3)?
The return on equity (ROE) of CM Hospitalar SA is 1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CM Hospitalar SA (VVEO3)?
On an EBIT basis the return on assets of CM Hospitalar SA is 3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CM Hospitalar SA (VVEO3)?
The operating margin of CM Hospitalar SA is 4.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CM Hospitalar SA (VVEO3)?
Revenue at CM Hospitalar SA is growing +1.7% versus a year earlier (3y avg +9.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CM Hospitalar SA (VVEO3)?
Earnings per share at CM Hospitalar SA are growing −92.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CM Hospitalar SA (VVEO3) generate?
The free cash flow of CM Hospitalar SA is R$125M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CM Hospitalar SA (VVEO3) carry?
The net debt of CM Hospitalar SA is R$2.9B (fiscal year 2025, ≈ 22.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CM Hospitalar SA in the live analysis
One click puts CM Hospitalar SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
